A team of scientists has identified an enzyme called PurF as a new drug target for tuberculosis, offering a fresh line of ...

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology ...

MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics today announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-molecule ...

The investment will fund the Phase I/Ib study of CGX-926 for MC4R-deficient genetic obesity in healthy subjects and patients.

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology ...

For years, a protein inside our cells has quietly powered billions of dollars' worth of cancer drugs. Now a team of ...

Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Find out how self-driving labs utilise data-driven approaches to enhance drug discovery efficiency and innovation.